Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05028764 · ClinicalTrials.gov registry record
Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers
A clinical trial, sponsored by Larimar Therapeutics.
- Completed
- Registry status
- 60
- Enrollment target
NCT05028764 is a clinical trial that has completed, run by Larimar Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT05028764 has completed, sponsored by Larimar Therapeutics.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
To examine range of tissue frataxin (FXN) concentrations, specific ribonucleic acids, other proteins and specialized lipids in the buccal cells, blood, and skin cells of normal healthy volunteers without Friedreich's ataxia (FRDA).
Interventions
- DIAGNOSTIC_TEST Buccal Swabs, Blood Draws and Skin Punch Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-08-04 |
| Est. Completion | 2022-02-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05028764
The ClinicalTrials.gov registry entry for NCT05028764 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Larimar Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Buccal Swabs, Blood Draws and Skin Punch Biopsy is the first listed.
NCT05028764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05028764 about?
NCT05028764 is a clinical study titled "Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers". To examine range of tissue frataxin (FXN) concentrations, specific ribonucleic acids, other proteins and specialized lipids in the buccal cells, blood, and skin cells of normal healthy volunteers without Friedreich's ataxia (FRDA).
What is the current status of trial NCT05028764?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2021-08-04. Estimated completion is 2022-02-04.
What interventions are being tested in trial NCT05028764?
The interventions under investigation include: Buccal Swabs, Blood Draws and Skin Punch Biopsy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05028764?
This trial is sponsored by Larimar Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.